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a  b  s  t  r  a  c  t
Background:  After measurement  of ofﬁce  blood  pressure  (BP)  and  ambulatory  BP  monitoring  (ABPM),
4  groups  of patients  were  identiﬁed  namely:  (i)  sustained  normotensive  patients  (BPs  are normal  both
clinically and  by  ABPM);  (ii)  white  coat  hypertensive  patients  (clinical  BP  were  above  limits,  but ABPM
were  normal);  (iii)  masked  hypertensive  patients  (clinical  BP  were  normal,  but  ABPM  were  high);  (iv)
sustained  hypertensive  patients  (both  ofﬁce  and  ABPM  were  high).  The  exact  pathophysiologic  mech-
anisms  of  these  conditions  are  not  exactly  known.  Besides  in the  literature  there  are  only  few  studies
that  compare  the  4  groups  of  patients  together.  Thus  the  study  was  carried  out to  compare  patients
with  sustained  normotension  (SNT),  white  coat  hypertension  (WCHT),  masked  hypertension  (MHT),  and
sustained  hypertension  (SHT).
Methods:  All patients  underwent  history  taking,  physical  examination,  laboratory  analysis,  and  ABPM.
They  were  referred  to the cardiology  department  for echocardiographic  evaluation.
Results:  In total  85  patients  with  SNT,  112  patients  with  WCHT,  31  patients  with  MHT,  and  81  patients
with  SHT  were  included.  Going  from  SNT  to SHT,  body  mass  index  (p < 0.0001),  waist  circumference
(p  <  0.0001),  fasting  blood  glucose  (p  = 0.002),  and  uric acid  (p = 0.029)  rose progressively.  Presence  of
metabolic  syndrome  was also  highest  in  SHT  and  lowest  in  SNT  (p  < 0.0001).
Conclusion:  Most  of the  metabolic  risk  factors  were  higher  in  patients  with  MHT  and  SHT  when  compared
to SNT  and WCHT.  Studies  are  needed  to determine  whether  metabolic  risk  factors  play  a causative  role
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Measurements of blood pressure (BP) were initially based
n auscultatory method with a mercury or aneroid sphygmo-
anometer. However, high BP variability with these methods led
o development of new methods including ambulatory BP monitor-
ng (ABPM). Accumulating evidence suggests that ABPM predicts
ardiovascular mortality and morbidity or end-stage renal disease
etter than ofﬁce BP measurements which is probably due to the
ower variability of BP measurements by these methods owing to
ultiple measurements and standardization of the circumstances
n which BP is measured. Based on this background, ABPM and
fﬁce BP were used to identify 4 groups of patients, namely: (i) sus-
ained normotensive patients (BPs were normal both clinically and
y ABPM); (ii) white coat hypertensive patients (clinical BPs were
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above limits, but ABPM were normal); (iii) masked hypertensive
patients (clinical BPs were normal, but ABPM were high); (iv) sus-
tained hypertensive patients (both ofﬁce and ABPM were high) [1].
Although in the literature many studies were performed in
patients with white coat, masked, and sustained hypertension,
only few studies compared the 4 groups of patients together [2,3].
Despite extensive research, these studies did not certainly tell
whether some conditions such as white coat hypertension has
prognostic signiﬁcance [4,5]. Additionally some of these studies
were performed in patients who  were already taking antihyper-
tensive medication. There is no doubt that more research is needed
regarding sustained normotension (SNT), white coat hypertension
(WCHT), masked hypertension (MHT), and sustained hypertension
(SHT). Thus the present study was conducted to compare demo-
graphic, laboratory, and clinical parameters among patients with
hitherto treated SNT, WCHT, MHT, and SHT.Materials and methods
The study had a cross-sectional design. The study was  in accor-
dance with the declaration of Helsinki; informed consent was
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btained from all patients before enrollment. A local ethics com-
ittee approved the study. The study included people attending
or the ﬁrst time a nephrology outpatient clinic. Patients with
econdary hypertension, liver disease, symptomatic heart fail-
re, neurologic disorders or deﬁcits, and pulmonary, autoimmune,
ndocrine (including type 1 and type 2 diabetic patients), malig-
ant diseases, and patients with urinary tract infection were not
ncluded in the study. Patients with serum creatinine >1.4 mg/dL
ere not included. None of the patients had a history of acute
oronary syndrome, myocardial infarction, angina pectoris, or coro-
ary revascularization procedure. Patients had no history of stroke,
arotid revascularization procedure, ischemic leg ulcer, peripheral
evascularization, or amputation. On 12-lead electrocardiogram, all
atients had normal sinus rhythm and no conduction disturbances.
None of the patients were shift workers and none of them
eported alcohol intake. Body mass index (BMI) was  calculated
s the ratio of dry weight in kilograms to height squared (in
quare meters).Waist circumference (WC) was measured midway
etween the lower rib margin and the iliac crest.
Twenty-four-hour urine specimens were collected to determine
reatinine clearance after spot urine examination. If the urinary
reatinine excretion of the two consecutive specimens differed by
ore than 10%, another 24-h collection was made to assess the
dequacy of collection.
The deﬁnition of SNT, WCHT, MHT  and SHT were as follows,
espectively:
ofﬁce systolic and diastolic BP <140/90 mmHg  and mean daytime
ABP <135/85 mmHg;
ofﬁce systolic and diastolic BP ≥140/90 mmHg  and mean daytime
ABP <135/85 mmHg;
ofﬁce systolic and diastolic BP <140/90 mmHg  and mean daytime
ABP ≥135/85 mmHg; and
ofﬁce systolic and diastolic BP ≥140/90 mmHg  and mean daytime
ABP time BP ≥135/85 mmHg  [6].
fﬁce blood pressure measurement
Ofﬁce BP measurements were performed using a mer-
ury sphygmomanometer. Adequate size cuffs (standard cuff of
3 cm × 12 cm or a large cuff of 34 cm × 15 cm)  according to arm
ircumference were applied round the non-dominant arm. First
nd ﬁfth phases of Korotkoff sounds were taken as the systolic and
iastolic BP, respectively. The measurements were taken after the
atients had rested for 10 min  in sitting position, with the arm com-
ortably placed at the heart level. Two measurements were taken
t 5-min intervals. Each set of two measurements was averaged to
ive the ofﬁce systolic and diastolic BP.
mbulatory blood pressure measurement
Ambulatory 24-h BP monitoring was performed on each
atient’s non-dominant arm using a SpaceLabs (Redmond, WA,
SA) 90207 oscillometric monitor concomitantly with ultrasono-
raphy (within 1 week). The accuracy of the device was  checked
gainst the standard auscultatory method to ensure that the dif-
erence in BP measurements between methods did not exceed
5 mmHg. The device was set to obtain BP readings at 20-min
ntervals during the day (07:00 AM–11:00 PM)  and at 30-min inter-
als during the night (11:00 PM–07:00 AM). Each ambulatory BP
onitoring dataset was ﬁrst automatically scanned to remove arti-
actual readings according to preselected editing criteria. Data were
dited by omitting all readings of zero, all heart rate readings <20
r >200, diastolic BP readings >150 and <40 mmHg, systolic BP
eadings >240 and <70 mmHg, and all readings where the differ-
nces between systolic and diastolic BPs was less than 10 mmHg.y 61 (2013) 222–226 223
Readings were evaluated if the percentage of successful readings
was above 90%. The following ABPM parameters were evaluated:
average ambulatory daytime systolic and diastolic BP levels (awake
period), average ambulatory nighttime systolic and diastolic BP
levels (asleep period), average ambulatory 24-h systolic and dia-
stolic BP levels, and mean ambulatory daytime, nighttime, and
24-h arterial BPs. Average ambulatory daytime, nighttime, and
24-h heart rates were also determined. All subjects were instructed
to rest or sleep between 11:00 PM and 7:00 AM (nighttime) and
to continue their usual activities between 7:00 AM and 11:00 PM
(daytime). Patients were asked to remain still at the time of mea-
surement and to note in a diary the occurrence of unusual events or
poor sleep. “Nocturnal dipping” was deﬁned as a reduction of >10%
(when compared with the daytime values) in the systolic and/or
diastolic BP levels at night. Left ventricular hypertrophy was eval-
uated by electrocardiography using Sokolow–Lyon voltage (sum of
the amplitude of the S wave in lead V1 and the R wave in lead V5
or V6 >35 mm)  [7].
Besides these procedures, patients were referred to measure
ecocardiographic parameters.
Echocardiography was  performed with a commercially avail-
able ultrasound system (Acuson Sequoia C256, Mountain View,
CA, USA) using a broadband transducer (3V2c). Two-dimensional,
M-mode, color measurements were recorded. Interventricular sep-
tum thickness and ejection fraction were measured. The peak
velocities of early (E) and late (A) diastolic ﬁlling, and their ratio
(E/A), were also measured for all patients for the detection of dia-
stolic dysfunction.
Additionally presence of metabolic syndrome (MetS) was diag-
nosed based on Adult Treatment Panel (ATP) III criteria that deﬁned
MetS as a constellation of risk factors of metabolic origin, of
which three or more indicate that an individual has MetS. The 5
possible risk factors include abdominal obesity, as evidenced by
a waist circumference >102 cm in men  and >88 cm in women,
triglyceride levels ≥150 mg/dL, high-density lipoprotein choles-
terol levels <40 mg/dL in men  and <50 mg/dL in women, blood
pressure ≥130/85 mmHg, and a fasting glucose level ≥110 mg/dL
[8].
Statistics
All values are expressed as mean ± standard deviation or as a
percentage (%). Data were analyzed using the program SPSS 15.0 for
Windows (SPSS, Inc., Chicago, IL, USA). The normality of data was
tested using the Kolmogorov–Smirnov test. Parameter differences
among the 4 groups were evaluated using the one-way ANOVA
Test for normally distributed variables and Kruskal–Wallis test for
non-normally distributed variables. For post hoc analysis of nor-
mally distributed variables Tukey’s b test was  used. For post hoc
analysis of non-normally distributed variables Benferroni corrected
Mann–Whitney U-test was used. For the comparison of categor-
ical variables, Chi-square test or Fisher’s exact test was used as
appropriate. Lastly multiple multivariate logistic regression anal-
yses related with WCHT, MHT  and SHT (as dependent variables).
A value of p < 0.05 was accepted as statistically signiﬁcant.
Results
Initially 340 patients were included. Four patients were
excluded due to atrial ﬁbrillation. One patient with renal artery
stenosis, 2 patients with hypothyroidism, and 1 patient with hyper-
thyroidism, 6 patients with type 2 diabetes, 1 patient with type 1
diabetes, and 4 patients with urinary tract infection were excluded;
12 patients with creatinine >1.4 mg/dL were also excluded. The
study was conducted in the remaining 309 patients. Patients were
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Table 1
The comparative demographic, clinical, and laboratory parameters among the 4 groups of patients.
Group I (N = 85) Group II (N = 112) Group III (N = 31) Group IV (N = 81) p-Value
Age (years)a 47.8 ± 12II,III,IV 56.8 ± 11.7I 60.7 ± 10.2I 59.1 ± 9.9I <0.0001**
Gender (male/female) (N) 58/27 83/29 19/12 47/34 0.110***
Body mass index (kg/m2)a 25.9 ± 3.0III,IV 26.2 ± 2.5III,IV 27.9 ± 4.7I,II,IV 29.8 ± 2.9I,II,III <0.0001**
Waist circumference (cm) 86.6 ± 5.7III,IV 87.3 ± 3.6III,IV 92.9 ± 8.7I,II 93.1 ± 7.6I,II <0.0001**
Smoker/non-smoker (N) 25/60IV 33/79IV 14/17 38/43I,II 0.029***
Dipper vs. non-dipper (N) 56/29 68/44 23/8 48/33 0.439***
Metabolic syndrome (present/absent) (N) 3/82II,III,IV 28/84I,IV 9/22I,IV 46/35I,II,III <0.0001***
Fasting blood glucose (mmol/L)a 5.17 ± 0.70II,III,IV 5.78 ± 1.47I 5.93 ± 1.86I 6.22 ± 2.21I 0.002**
Blood urea nitrogen (mmol/L)a 5.11 ± 1.57 5.5 ± 1.61 5.68 ± 1.82 5.75 ± 1.86 0.089**
Creatinine (mol/L)a 74.3 ± 18.6IV 74.1 ± 16.8IV 81.3 ± 20.3 81.6 ± 18.6I,II 0.027**
Albumin (g/L)a 43.9 ± 3.5 44.2 ± 5.0 45.1 ± 3.8 44.7 ± 3.8 0.450**
Hemoglobin (g/L)a 140.7 ± 32.3 138.2 ± 11.0 138.6 ± 14.6 138.9 ± 11.9 0.845**
Sodium (mmol/L)a 140.5 ± 8.37 139.4 ± 3.44 1401 ± 3.07 140.3 ± 5.27 0.485**
Potassium (mmol/L)a 4.31 ± 0.32 4.31 ± 0.37 4.42 ± 0.43 4.37 ± 0.39 0.291**
Calcium (mmol/L)a 2.31 ± 0.10 2.33 ± 0.09 2.30 ± 0.14 2.33 ± 0.11 0.280**
Phosphorus (mmol/L)a 1.11 ± 0.16 1.12 ± 0.16 1.06 ± 0.15 1.12 ± 0.18 0.368**
Uric acid (mol/L)a 303.9 ± 89.8IV 312.9 ± 77.3 328.9 ± 83.9 341.4 ± 94.6I 0.029**
Alanine amino transferase (kat/L)a 0.41 ± 0.22 0.40 ± 0.17 0.42 ± 0.13 0.38 ± 0.15 0.481**
Aspartate amino transferase (kat/L)a 0.36 ± 0.22 0.36 ± 0.14 0.40 ± 0.14 0.34 ± 0.11 0.370**
Total cholesterol (mmol/L)a 5.18 ± 0.93 5.35 ± 1.06 5.39 ± 0.89 5.41 ± 1.21 0.445**
LDL-cholesterol (mmol/L)a 3.05 ± 0.77 3.12 ± 0.84 3.29 ± 0.76 3.22 ± 0.95 0.589**
HDL-cholesterol (mmol/L)a 1.35 ± 0.33 1.41 ± 0.31 1.37 ± 0.31 1.34 ± 0.32 0.393**
Triglyceride (mmol/L)a 1.42 ± 0.68 1.59 ± 0.69 1.66 ± 0.82 1.68 ± 0.82 0.060**
Spot urine proteinuria present/absent (N) 3/82 6/106 3/28 11/70 0.064***
Thyroid stimulating hormone (mU/L)a 1.65 ± 1.10 1.53 ± 1.33 1.13 ± 0.67 1.61 ± 1.24 0.210**
Hs-Crp (mg/L)a 3.79 ± 3.05 4.45 ± 4.10 4.94 ± 3.93 5.11 ± 4.23 0.220**
Creatinine clearance (ml/min)/1.73 m2a 90.8 ± 22.6III,IV 85.4 ± 19.6 76.2 ± 18.0I 80.6 ± 19.2I 0.001**
SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Hs-Crp, high-sensitivity C-reactive protein.













G** p-Value is based on one way ANOVA test.
*** p-Value is based on Chi-square test or Fisher’s exact test as appropriate.
roups with signiﬁcant differences according to the post hoc Tukey’s b test and Ben
ivided into 4 groups according to the clinical and ambulatory BP
easurements as deﬁned above:
Group I (N = 85) was composed of patients with SNT;
Group II (N = 112) was composed of patients with WCHT;
Group III (N = 31) was composed of patients with MHT;
Group IV (N = 81) was composed of patients with SHT.
The comparative demographic, clinical, and laboratory param-
ters among the 4 groups of patients are given in Table 1. The
omparative clinical and ambulatory BPs are shown in Table 2.
mong 309 patients, 243 underwent echocardiography (others
efused to do so). The comparison of electrocardiographic and
chocardiography ﬁndings among the 4 groups of patients is given
n Table 3.
able 2
he comparative ofﬁce and ambulatory blood pressure and heart rate parameters among
Group I (N = 85) Gr
Ofﬁce SBP (mmHg)a 122.6 ± 9.7II,IV 15
Ofﬁce DBP (mmHg)a 76.8 ± 6.78II,IV 9
Average ambulatory SBP (mmHg) (daytime)a 118.8 ± 7.6III,IV 12
Average ambulatory DBP (mmHg) (daytime)a 73.2 ± 5.7III,IV 7
Average ambulatory SBP (mmHg) (nighttime)a 108.3 ± 11.1III,IV 11
Average ambulatory DBP (mmHg) (nighttime)a 65.6 ± 7.9IV 6
Average ambulatory SBP (mmHg) (24-h)a 116.6 ± 7.8III,IV 12
Average ambulatory DBP (mmHg) (24-h)a 71.6 ± 5.6III,IV 7
Mean ambulatory arterial BP (mmHg) (daytime)a 88.4 ± 5.9III,IV 8
Mean ambulatory arterial BP (mmHg) (nighttime)a 79.9 ± 8.5III,IV 8
Mean ambulatory arterial BP (mmHg) (24-h)a 85.0 ± 6.2III,IV 8
Mean ambulatory heart rate (beats/min) (daytime)a 75.5 ± 9.92 7
Mean ambulatory heart rate (beats/min) (nighttime)a 64.5 ± 8.1 6
Mean ambulatory heart rate (beats/min) (24-h)a 73.4 ± 7.9 7
BP, systolic blood pressure; DBP, diastolic blood pressure.
a Mean ± standard deviation.
** p-Value is based on one way ANOVA test.
roups with signiﬁcant differences according to the post hoc Tukey’s b test are shown in i corrected Mann–Whitney U-test test was shown in superscript roman.
Additional subgroup analysis was  performed in patients who
were extreme nocturnal dippers and reverse dippers. Extreme
nocturnal dipping was deﬁned as reduction in average SBP and
DBP at night ≥20% when compared to daytime. Reverse dip-
ping was  deﬁned as higher nocturnal average SBP and DPB in
comparison with daytime values [9]. Among 309 patients, 177
patients were dippers, 67 were non-dippers, 18 were extreme
dippers, and 47 were reverse dippers. Comparison of laboratory
variables among these 4 groups of patients showed that only uric
acid levels were different among the groups (297.4 ± 88.0 mol/L,
350.9 ± 79.7 mol/L, 310.5 ± 75.5 mol/L, and 356.9 ± 70.8 mol/L
in dippers, in non-dippers, in extreme dippers, and in reverse
dippers, respectively, p < 0.0001). Post hoc analysis revealed that
uric acid levels were different between dippers and non-dippers
(p < 0.0001) and between dippers and reverse dippers (p < 0.0001).
 the 4 groups of patients.
oup II (N = 112) Group III (N = 31) Group IV (N = 81) p-Value
1.3 ± 16.8I,III,IV 128.8 ± 9.4II 159.4 ± 21.6I,II <0.0001**
3.7 ± 9.60I,III 79.3 ± 6.99II,IV 96.8 ± 9.44I,III <0.0001**
2.2 ± 7.9III,IV 143.2 ± 7.6I,II 146.3 ± 13.8I,II <0.0001**
2.0 ± 6.7III,IV 79.1 ± 7.3I,II,IV 83.9 ± 10.9I,II,III <0.0001**
3.5 ± 11.2III,IV 129.2 ± 16.3I,II 132.6 ± 17.5I,II <0.0001**
5.4 ± 8.0IV 69.9 ± 8.8 74.2 ± 8.5I,II <0.0001**
0.4 ± 7.9III,IV 140.3 ± 9.3I,II 143.5 ± 14.1I,II <0.0001**
0.4 ± 6.6III,IV 77.3 ± 7.1I,II 81.3 ± 8.6I,II <0.0001**
8.7 ± 6.4III,IV 100.3 ± 4.9I,II,IV 104.6 ± 9.3I,II,III <0.0001**
1.5 ± 8.3III,IV 89.7 ± 10.3I,II 93.7 ± 9.1I,II <0.0001**
5.8 ± 6.3III,IV 96.1 ± 6.1I,II,IV 100.2 ± 7.9I,II,III <0.0001**
3.7 ± 13.8 74.1 ± 9.2 75.3 ± 9.2 0.713**
6.3 ± 10.4 65.0 ± 7.9 67.7 ± 9.3 0.448**
2.2 ± 10.1 72.1 ± 9.3 73.7 ± 8.6 0.843**
superscript roman.
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Table  3
Comparison of electrocardiographic and echocardiographic ﬁndings among the 4 groups of patients.
Group I (N = 59) Group II (N = 95) Group III (N = 25) Group IV (N = 64) p-Value
Left ventricular hypertrophy (based on
electrocardiography) present/absent (N)
7/78III,IV 14/98III,IV 9/22I,II 27/54I,II <0.0001***
Interventricular septum thickness (mm)a 1.06 ± 0.14II,III,IV 1.18 ± 0.22I,IV 1.23 ± 0.12I 1.27 ± 0.14I,II <0.0001**
Ejection fraction (%)a 59.6 ± 5.2 58.3 ± 8.1 58.1 ± 8.5 56.7 ± 8.5 0.235**
Diastolic dysfunction (present/absent) (N) 10/49II,III,IV 31/64I,III,IV 15/10I,II 41/23I,II <0.0001***
E/A ratio 1.27 ± 0.20II,III,IV 1.17 ± 0.29I,III,IV 0.93 ± 0.24I,II 0.88 ± 0.22I,II <0.0001***
a Mean ± standard deviation.
** p-Value is based on one way ANOVA test.













































i*** p-Value is based on Chi-square test.
roups with signiﬁcant differences according to the post hoc Tukey’s b test are sho
omparison of categorical variables including gender, smoking sta-
us, electrographically determined ventricular hypertrophy, spot
rine proteinuria, and presence of MetS demonstrated no dif-
erence among groups. Lastly, comparison of echocardiographic
arameters including interventricular septum thickness, ejection
raction, E/A ratio, and presence of diastolic dysfunction were not
ifferent among these patients.
Additional multiple multivariate logistic regression analyses
ere performed to investigate the independent parameters includ-
ng gender, age, smoking status, BMI, presence of metabolic
yndrome, presence of spot urine proteinuria, presence of diastolic
ysfunction, interventricular septum thickness, ejection fraction,
asting blood glucose, uric acid, high-sensitivity C-reactive pro-
ein, and creatinine clearance related with WCHT, MHT, and SHT
as dependent variables). The results showed that WCHT was
elated with age (odds ratio: 1.054, 95%CI: 1.004–1.106, p = 0.034)
nd with smoking status (odds ratio: 2.829, 95%CI: 1.222–6.552,
 = 0.015). MHT  was associated only with creatinine clearance
odds ratio: 0.960, 95%CI: 0.924–0.997, p = 0.036). Finally, SHT
as independently associated with being male (odds ratio: 4.184,
5%CI: 1.445–10.869, p = 0.003), BMI  (odds ratio: 1.247, 95%CI:
.088–1.430, p = 0.002), and presence of MetS (odds ratio: 3.555,
5%CI: 1.275–8.771, p = 0.014).
iscussion
The current study demonstrated that most of the metabolic and
linical characteristics were different in patients with SNT, WCHT,
HT, and SHT. Additionally the comparison of the prevalence of
etS was ﬁrstly carried out among the 4 groups of patients.
Although various studies have been performed in these subjects
ebate is going on regarding the clinical signiﬁcance of these con-
itions. For example, it is still not clear whether presence of WCHT
ortends future risk for cardiovascular complications. While some
tudies suggested WCHT as a risk factor [10,11], others showed
hat patients with WCHT had favorable prognosis [12–14].  Thus the
rognostic signiﬁcance of WCHT remains controversial [5].  Besides
hese conﬂicting issues, there are few studies comparing these 4
roups of patients. In one of these studies, 4 groups of patients were
ompared longitudinally with respect to cardiovascular mortality
nd stroke. The authors showed that patients with WCHT were sim-
lar to patients with SNT. However, risk was signiﬁcantly higher for
ubjects with MHT  and SHT [2].  In another study, it was  shown that
he incidence and risk of cardiovascular death showed a progres-
ive increase from subjects in which in-ofﬁce and out-of-ofﬁce BPs
ere both normal to subjects with WCHT, MHT, and in-ofﬁce and
out-of-ofﬁce” HT, independent of age and gender [3].
Although these studies were valuable, no detailed comparison
as performed with regard to demographic, laboratory, and clinical
ndings. Thus the current study was performed to highlight these
ssues.superscript roman.
One of the important ﬁndings of the present study was  the
progressive rise of various metabolic risk factors including BMI,
WC,  fasting blood glucose, and uric acid going from SNT to SHT.
Also the prevalence of MetS was lowest in patients with SNT and
highest in patients with SHT. These ﬁndings raise the probability
that metabolic risk factors may  play a role for the development of
MHT  and SHT. Indeed Mancia et al. demonstrated that serum glu-
cose and BMI  has been associated with the development of SHT
[11]. In another study, it was  also demonstrated that BMI  and WC
were higher in patients with SHT when compared to normotensive
patients [15]. Even patients with WCHT have been found to have
increased risk for the presence of MetS when compared to patients
with SNT [16]. Why  are these metabolic risk factors related with
MHT  and SHT? Although the current study did not aim to explore
pathophysiologic relationships some speculations can be made. It is
already known that excess weight leads to both structural and func-
tional abnormalities in many systems of the body, as well as a higher
risk of death from all causes, including cardiovascular diseases, and
increases parallel to the range of moderate to severe weight excess
in all age groups [17]. It was also found that the prevalence of SNT
was signiﬁcantly higher in underweight cases than normal weight
and overweight cases [18]. Thus, the dominant underlying risk fac-
tor for the MetS appears to be already existing excess weight or a
trend toward excess weight, which is probably the main cause of
insulin resistance, dyslipidemia, IGT, and elevated BP [19].
Abdominal obesity a key element of MetS, initiates increased
sympathetic outﬂow, increased arterial resistance, and ultimately
the development of increased BP by many pathways that are still
poorly understood [20]. Visceral adiposity has been found also
to induce increased large artery stiffness in both younger and
older persons [19]. Additionally, recent evidence demonstrated
that pericardial fat tissue was related to MetS, coronary artery
disease, and diastolic dysfunction [21]. It was  also shown that
epicardial fat tissue was  associated with hypertension [22]. Thus,
the relationship between MetS and WCHT, MHT,  and SHT may  be
explained in the context of epicardial fat tissue. Increased serum
uric acid levels going from SNT to SHT may  also be responsi-
ble for the present ﬁndings regarding the increased prevalence
of MetS as going from SNT to SHT since uric acid itself, inde-
pendent of other factors, was suggested to be responsible for
derangement of metabolism and blood pressure [23]. Another
potential explanation for the high incidence of MetS in SHT may
be the activation of renin–angiotensin–aldosterone system (RAAS).
Mechanisms involved in activation of the RAAS in obesity include
sympathetic stimulation, synthesis of adipokines in the RAAS by
visceral fat, and hemodynamic alterations [24]. Activation of the
RAAS and the sympathetic nervous system—as well as physical
compression of the kidneys by visceral adiposity which impairs
normal pressure natriuresis, increases renal tubular sodium reab-
sorption, and causes volume expansion and hypertension [25]. Last
but not the least the relationship between MetS and SHT may  be
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alt sensitivity has been associated with hypertension and the MetS
26]. Thus all aforementioned factors may  explain the increased
revalence of MetS as going from patients with SNT to SHT.
The electrocardiographically determined left ventricular hyper-
rophy and echocardiographically determined interventricular
eptum thickness were found to be higher in MHT and SHT when
ompared to SNT and WCHT which were in accord with the litera-
ure. Previous studies have also demonstrated that patients with
HT  are more likely to have left ventricular hypertrophy than
ormotensive subjects, assessed in terms of left ventricular mass
27–29], posterior wall thickness [30], or the prevalence of left ven-
ricular hypertrophy [31]. Thus it was suggested that MHT  patients
ad similar cardiovascular prognosis comparable to those of true
ypertensive patients and patients with MHT  and SHT are not fun-
amentally different from each other, but represent a different
henotypic expression of high BP [32,33]. Of note there was  no
ifference regarding spot urine proteinuria as a measure of target
rgan damage. However the prevalence of proteinuria in the whole
opulation is low overall and the lack of association between HT
ubtypes and proteinuria may  be due to this low prevalence.
This study has some limitations that deserve mention. Firstly,
ince the study is cross-sectional, cause and effect relationships
annot be suggested. Secondly, the measurements were made only
nce, raising the question of reproducibility. Thus serial measure-
ents would be better for the interpretation of results. Thirdly, the
esults could not be generalized to other patients such as those
ith diabetes and taking medications since these patients were
xcluded. Fourthly, calculation of left ventricular mass index was
ot speciﬁcally concerned. Lastly, although it was accepted that
onventional (clinic/ofﬁce) BP measurements and ABPM were ade-
uate for classiﬁcation of patients as WCHT, MHT, etc. [34], it would
e better if home or self blood pressure monitoring data were avail-
ble for the patients.
In conclusion this is one of the few studies to compare patients
ith SNT, WCHT, MHT, and SHT with respect to various demo-
raphic, clinical, and laboratory parameters. Most of the metabolic
isk factors were higher in patients with MHT  and SHT when com-
ared to SNT and WCHT. Studies are needed to determine whether
etabolic risk factors play a causative role for the development of
HT  and SHT.
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